Navigation Links
YM sees nimotuzumab license unaffected by civil claim against licensor
Date:3/2/2010

MISSISSAUGA, ON, March 2 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE YMI, TSX:YM), announces that it filed a Form 6K describing that certain US patents for nimotuzumab licensed to YM's majority-owned Canadian subsidiary , CIMYM BioSciences Inc., have become subject to a lien in the United States, pursuant to a court order, to a third party. The lien is a consequence of a dispute unrelated to either YM, its licensor, or the patent owner, the Center of Molecular Immunology (CIM). Counsel has advised the Company that the lien does not affect the exclusive, royalty-free license for nimotuzumab issued by CIMAB S.A. to CIMYM for numerous territories, including the US.

None of the international patents for nimotuzumab for which YM is licensed are affected.

"We do not believe that this situation will have an impact on YM's continuing development of nimotuzumab in the US nor do we expect it to be material to YM," said Da
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA
2. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING
3. YM BIOSCIENCES REPORTS POSITIVE NIMOTUZUMAB FOUR-YEAR SURVIVAL DATA PRESENTED AT ASTRO 2009
4. YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG
5. YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR MARKETING IN MEXICO
6. YM BIOSCIENCES USA RECEIVES CLEARANCE FROM US TREASURY DEPARTMENT TO EXTEND CLINICAL PROGRAM FOR NIMOTUZUMAB
7. YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB
8. NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS
9. YM BIOSCIENCES ANNOUNCES RESULTS OF RANDOMIZED NIMOTUZUMAB STUDY TO BE PRESENTED IN A POSTER AT ASCO ANNUAL MEETING
10. YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER
11. YM BIOSCIENCES NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; ... proprietary technologies and products for advanced microarray diagnostics, today ... fiscal quarter ended March 31, 2015. ... with our existing customers and to develop new opportunities," ... SQI. "The delivery of a fully automated sqidlite™ system ...
(Date:5/21/2015)... 2015 Seventh Wave Laboratories, a consulting-based ... of pharmaceutical products and medical devices, announced the purchase ... a 50,000 sq. ft. building more than three times ... growth. Facility renovations will begin immediately and the gradual ... occur in September. , “We are excited about ...
(Date:5/21/2015)... 21, 2015 Specialty Pharmacy Times ... been admitted to BPA Worldwide as a business ... track audience data for Specialty Pharmacy Times based ... “By becoming a member of BPA Worldwide, Specialty ... our clients with the most reliable, unequaled data,” ...
(Date:5/21/2015)... 21, 2015  Susan Hedstrom, Executive Director of ... organization dedicated to supporting research to advance the ... today that FPWR has received the organization,s largest ... contributed $1 million in support of the ... "Our gift signifies our ...
Breaking Biology Technology:SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8Seventh Wave Laboratories Purchases Building for Expansion, Upcoming Move 2Seventh Wave Laboratories Purchases Building for Expansion, Upcoming Move 3Specialty Pharmacy Times Joins BPA Worldwide 2The Foundation for Prader-Willi Research Receives $1M Contribution in Support of Clinical Initiatives 2
... 6 Hovione announces that it has,purchased ... Zhejiang provincial,authorities have already issued the necessary ... now operational., The acquisition provides Hovione ... and strengthens its 20 year,presence in China. ...
... Function Now Available in the US, SINGAPORE, ... new product called NeuroAid10(TM) in the US market ... and is a combination of ten all-natural ingredients. ... the best of Asian,and Western medicine., Since ...
... Calif., March 6 Senetek PLC (OTC,Bulletin Board: ... development,of technologies that target the science of healthy ... two Veteran Sales and Marketing Executives,and the appointment ... Campagnoli joined the Company in December and has ...
Cached Biology Technology:Hovione Buys Drug Manufacturing Facility in China 2Moleac Launches NeuroAid10(TM) in the United States 2Moleac Launches NeuroAid10(TM) in the United States 3Senetek PLC Announces Appointments of Key Personnel 2Senetek PLC Announces Appointments of Key Personnel 3
(Date:5/21/2015)... According to a new ... Software, Services), by Applications (Surveillance (Airborne, Maritime, Land), ... (Military & Defense & Commercial) - Global Forecast ... is expected to grow from $7252.0 Million in ... Compound Annual Growth Rate (CAGR) of 6.6%. ...
(Date:5/21/2015)... , May 21, 2015 The Sync ... of music for health, today announced a collaborative partnership ... The partnership will center on collaboration on original research, ... first step in the collaboration, The Sync Project and ... "Music as Medicine" in the 2015-2016 academic year.  ...
(Date:5/20/2015)... May 20, 2015 ... has announced the addition of the  ... Iris Recognition Market"  report to their ... research service analyses trends in the ... and commercial sectors, globally. Despite hardware ...
Breaking Biology News(10 mins):Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2
... mulch offers a range of benefits and has become ... horticultural crops. Despite the recognized benefits, the plastic mulches ... be used for only one cropping season, after which ... and time-consuming processes for growers. The challenges and costs ...
... cities: safety, ready availability of infrastructure, plenty of company ... for the benefits of country life, such as clean ... and particularly birds, face the same choice between living ... avoiding disadvantages of larger colonies such as the increased ...
... stage medical device company founded by students at The ... at the Texas Life Science Forum as one of ... having the best business opportunity and promise for high ... competed in the event on Thursday, February 20 in ...
Cached Biology News:Study finds 2 biodegradable mulches to be suitable polyethylene alternatives 2The importance of (experimental) design 2The importance of (experimental) design 3Leto Solutions honored as 1 of top 10 best companies at 2014 Texas Life Science Forum 2Leto Solutions honored as 1 of top 10 best companies at 2014 Texas Life Science Forum 3
Anti-Human Factor XI Purified (Polyclonal) (sheep IgG)...
...
This antibody detects an ~25 kDa band, corresponding to the expected molecular mass of Rab3A, on immunoblots. The antibody specificity is confirmed in peptide inhibition immunoblotting studies....
HLA II DG+DR+DP Monoclonal Antibody, Purified, Unconjugated, Clone: IQU9 This antibody is specific for the monomorphic determinant of the HLA Class II beta chains of the human MHC (28 kDa)....
Biology Products: